Table 3. Treatment-related adverse events (incidence of ≥1%).
| Treatment-related adverse event | BBFC N=435, n (%) | Brinzolamide N=460, n (%) | Brimonidine N=455, n (%) |
|---|---|---|---|
| Ocular | |||
| Vision blurred | 23 (5.3%) | 30 (6.5%) | 1 (0.2%) |
| Eye irritation | 18 (4.1%) | 6 (1.3%) | 10 (2.2%) |
| Eye allergy | 11 (2.5%) | 0 (0%) | 5 (1.1%) |
| Ocular hyperemia | 9 (2.1%) | 3 (0.7%) | 15 (3.3%) |
| Eye pain | 9 (2.1%) | 8 (1.7%) | 5 (1.1%) |
| Conjunctivitis allergic | 8 (1.8%) | 2 (0.4%) | 7 (1.5%) |
| Eye pruritus | 7 (1.6%) | 5 (1.1%) | 3 (0.7%) |
| Conjunctival hyperemia | 7 (1.6%) | 5 (1.1%) | 5 (1.1%) |
| Dry eye | 6 (1.4%) | 4 (0.9%) | 7 (1.5%) |
| Conjunctivitis | 6 (1.4%) | 1 (0.2%) | 8 (1.8%) |
| Foreign body sensation in eyes | 5 (1.1%) | 3 (0.7%) | 2 (0.4%) |
| Non-ocular | |||
| Dysgeusia | 17 (3.9%) | 38 (8.3%) | 1 (0.2%) |
| Dry mouth | 13 (3.0%) | 0 (0%) | 11 (2.4%) |
| Fatigue | 3 (0.7%) | 0 (0%) | 6 (1.3%) |
Abbreviation: BBFC, brinzolamide 1%/brimonidine 0.2% fixed combination.
Adverse events were analyzed using the safety population.